康龙化成(03759)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03759 康龙化成

交易中 06-15 15:22:45

15.570

+0.050

+0.32%

最高15.690	最低15.350	成交量278.54万
今开15.690	昨收15.520	日振幅2.19%
总市值284.93亿	流通市值54.96亿	总股本18.30亿
成交额4,311万	换手率0.79%	流通股本3.53亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03759","market":"HK","secType":"STK","nameCN":"康龙化成","latestPrice":15.57,"timestamp":1781508164690,"preClose":15.52,"halted":0,"volume":2785400,"delay":0,"changeRate":0.0032216494845361283,"floatShares":353000000,"shares":1830000000,"eps":1.088969449690093,"marketStatus":"交易中","change":0.05,"latestTime":"06-15 15:22:45","open":15.69,"high":15.69,"low":15.35,"amount":43110723,"amplitude":0.021907,"askPrice":15.58,"askSize":11100,"bidPrice":15.57,"bidSize":600,"shortable":3,"etf":0,"ttmEps":1.1007750239541132,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1781511000000},"marketStatusCode":2,"adr":0,"listingDate":1574870400000,"exchange":"SEHK","adjPreClose":15.52,"dividendRate":0.014893,"openAndCloseTimeList":[[1781487000000,1781496000000],[1781499600000,1781510400000]],"volumeRatio":0.463515,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"300759","market":"SZ","secType":"STK","nameCN":"康龙化成","latestPrice":22.47,"timestamp":1781506800000,"preClose":22.38,"halted":0,"volume":42825100,"delay":0,"premium":"-40.23"}},"requestUrl":"/m/hq/s/03759","defaultTab":"news","newsList":[{"id":"2643822932","title":"【券商聚焦】交银国际：医药行业上半年表现整体稳健 下半年内部分化或加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2643822932","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643822932?lang=zh_cn&edition=full","pubTime":"2026-06-15 10:21","pubTimestamp":1781490116,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，医药行业在1H26表现整体稳健、但内部分化也较为明显。短期关注出海交易、业绩表现和利好政策落地。推荐高景气度赛道中、投资性价比较高的头部玩家，包括药明合联、凯莱英和康龙化成。2026年港股龙头收入和净利润增速有望稳定在双位数。板块复苏积极信号已经出现。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983754","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0737861772.HKD","01951","01177","09996","LU0320764599.SGD","02268","06078","02273","06821","HK0000306685.HKD","LU0051755006.USD","06990","LU1960683339.HKD","01276","01093","LU0502904849.HKD","LU1242518857.USD","LU0348827113.USD","IE00B0JY6N72.USD","LU3063872942.SGD","03692","06996","01952","02269","02096","LU0140636845.USD","09966","09926","BK1576","LU0819121731.USD","LU1226287875.USD","HK0000320264.USD","01530","BK1191","00013","LU0181495838.USD","LU0456827905.SGD","LU2097828631.EUR","SG9999002562.SGD","LU1688375341.USD","IE00BZ08YR35.GBP","06160","LU1880383366.USD","03759","LU2399975544.HKD","01801","01548","02162","02596","03329"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167799238","title":"康龙化成宣派末期股息每股0.2元人民币，8月7日派付","url":"https://stock-news.laohu8.com/highlight/detail?id=1167799238","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167799238?lang=zh_cn&edition=full","pubTime":"2026-06-12 21:32","pubTimestamp":1781271133,"startTime":"0","endTime":"0","summary":"康龙化成发布更新公告，已批准宣派截至2025年12月31日止年度的末期普通股息，每10股派发人民币2元。公司预设以港元派付，按汇率1元人民币兑1.149637港元计算，折合每10股派发2.299274港元。股权登记日为2026年7月15日，除净日则定为7月7日。股东须于7月8日16:30前递交股份过户文件，股份过户登记将自7月9日至7月15日暂停。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康龙化成宣派末期股息每股0.2元人民币，8月7日派付","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642295159","title":"康龙化成(03759)将于8月7日派发末期现金股息每10股2.299274港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642295159","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642295159?lang=zh_cn&edition=full","pubTime":"2026-06-12 21:30","pubTimestamp":1781271024,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康龙化成(03759)发布公告，将于2026年8月7日派发截至2025年12月31日止年度的末期现金股息每10股2.299274港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","VIG","EWH","03759","BK1576","BK0216","300759","BK1141","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104720521","title":"康龙化成宣派末期股息每股0.2元人民币，H股派息日8月7日","url":"https://stock-news.laohu8.com/highlight/detail?id=1104720521","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104720521?lang=zh_cn&edition=full","pubTime":"2026-06-12 21:25","pubTimestamp":1781270753,"startTime":"0","endTime":"0","summary":"康龙化成(03759)公布2025年度利润分配方案，将向全体股东每1股派发现金红利人民币0.2元（含税），派息总额约3.66亿元人民币。\n此次末期股息的H股记录日期为2026年7月15日（星期三）。以人民币宣派的股息将向A股股东以人民币支付，向H股股东以港元支付，港元实际派发金额按年度股东会召开日前五个营业日中国人民银行公布的港元兑人民币平均汇率（1港元兑人民币0.869840元）折算。H股股息证预计于2026年8月7日（星期五）或前后寄发予已登记H股股东。\nA股股东的股权登记日及除息安排将另行通过深圳证券交易所公告发布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康龙化成宣派末期股息每股0.2元人民币，H股派息日8月7日","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642956902","title":"康龙化成(03759)委任楼柏良为第四届董事会执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2642956902","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642956902?lang=zh_cn&edition=full","pubTime":"2026-06-12 21:24","pubTimestamp":1781270652,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康龙化成(03759)发布公告，于年度股东会上，经与会股东选举，决议批准委任楼柏良博士、楼小强先生及郑北女士为第四届董事会执行董事，委任万璇女士为第四届董事会非执行董事，及委任李丽华女士、曾劲峰教授及沈蓉女士为第四届董事会独立非执行董事。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300759","03759","BK0216","BK1576","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642449356","title":"康龙化成：实控人楼小强补充质押400万股，累计质押57.77%持股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642449356","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642449356?lang=zh_cn&edition=full","pubTime":"2026-06-10 16:21","pubTimestamp":1781079660,"startTime":"0","endTime":"0","summary":"6月10日，康龙化成（300759/03759）发布公告，实际控制人之一楼小强将其持有的400万股进行补充质押，占其所持股份的6.61%及公司总股本的0.22%。截至公告披露日，楼小强累计质押股份数量为3497万股，占其持股总数的57.77%及公司总股本的1.90%。2026年一季度，康龙化成实现收入35.78亿元，归母净利润3.35亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606103766690527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1576","BK1141","03759","BK0216","300759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641105779","title":"医药外包概念股全线走低 金斯瑞生物科技(01548)跌7.43%、药明生物(02269)跌7.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2641105779","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641105779?lang=zh_cn&edition=full","pubTime":"2026-06-08 13:43","pubTimestamp":1780897412,"startTime":"0","endTime":"0","summary":"中邮证券表示，2026年第一季度，海外CXO行业整体呈现分化复苏格局，全球生物制药融资环境出现实质性改善，带动需求逐步回暖，但早期初创企业资金压力仍未完全缓解，不同细分赛道、不同规模企业的表现存在差异，行业结构性分化特征进一步凸显。展望2026年，海外头部CXO企业收入指引仍维持稳健小幅增长格局，叠加全球生物医药投融资逐步回暖、创新药研发需求稳步复苏，行业景气度延续上行态势，成长确定性进一步增强。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983281","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","LU2045819591.USD","LU0417516902.SGD","LU2242644610.SGD","09939","HK0000320264.USD","06127","LU1880383366.USD","BK1574","01521","159938","HK0000320223.HKD","LU0039217434.USD","LU0572944931.SGD","01873","03759","LU0516422952.EUR","LU0516422440.USD","BK1589","LU3063872942.SGD","LU0516422366.SGD","BK1521","LU0588546209.SGD","LU0140636845.USD","LU0417516738.SGD","01548","LU0856984785.SGD","LU0051755006.USD","HK0000306685.HKD","03347","LU0348735423.USD","LU0307460666.USD","LU1688375341.USD","02359","LU0708995583.HKD","LU1046422090.SGD","BK1191","LU0320764599.SGD","LU0456827905.SGD","LU1720050803.USD","BK1515","LU0359201612.USD","LU0516423091.SGD","SG9999002463.SGD","LU0348766576.USD","LU0348767384.USD","02269","06821","LU0326950275.SGD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641214116","title":"康龙化成(03759)选举李承宗为职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2641214116","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641214116?lang=zh_cn&edition=full","pubTime":"2026-06-05 17:03","pubTimestamp":1780650197,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康龙化成(03759)发布公告，本公司于2026年6月5日召开职工代表大会，并于会上选举李承宗先生为第四届董事会职工代表董事。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","03759","BK1141","300759","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641659118","title":"康龙化成：公司经营正常有序，不存在应披露而未披露的重大事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2641659118","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641659118?lang=zh_cn&edition=full","pubTime":"2026-06-05 15:18","pubTimestamp":1780643904,"startTime":"0","endTime":"0","summary":"证券之星消息，康龙化成(300759)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价已连续下跌5年，相对于最高价已经跌去80%。请问：（1）公司经营是否出现重大变故？（2）是否有未披露的利空？（3）基于什么理由认为公司不会退市？”康龙化成回复：尊敬的投资者您好，公司经营正常有序，不存在应披露而未披露的重大事项。股价波动受宏观经济环境、政策因素、资本市场情绪等多重因素影响，敬请投资者注意投资风险。感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500020524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK0216","03759","BK1576","300759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185376596","title":"康龙化成更新5月股份变动月报表，股本维持1,837,283,628股","url":"https://stock-news.laohu8.com/highlight/detail?id=1185376596","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185376596?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:43","pubTimestamp":1780476185,"startTime":"0","endTime":"0","summary":"康龙化成（北京）新药技术股份有限公司于2026年6月3日发布截至2026年5月31日的证券变动月报表。公告显示，公司法定/注册股本总额为人民币1,837,283,628元，较上月底无变动。根据公告，康龙化成现有H股普通股359,977,887股，包括非库存股份352,714,587股与库存股7,263,300股，本月无新增发行或转让，余额保持不变；A股普通股则为1,477,305,741股，无库存股份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640898960","title":"康龙化成获Ariel Investments, LLC增持53.34万股 每股作价约18.16港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640898960","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640898960?lang=zh_cn&edition=full","pubTime":"2026-06-01 07:26","pubTimestamp":1780269960,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新资料显示，5月26日，Ariel Investments， LLC增持康龙化成（03759）53.34万股，每股作价18.1646港元，总金额约为968.9万港元。增持后最新持股数目为2130.67万股，最新持股比例为6.04%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-06-01/doc-inhzwcks5473172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03759","EWH","BK1576","300759","BK1141","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639275256","title":"Ariel Investments, LLC增持康龙化成(03759)53.34万股 每股作价约18.16港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2639275256","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639275256?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:22","pubTimestamp":1780057370,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月26日，Ariel Investments, LLC增持康龙化成(03759)53.34万股，每股作价18.1646港元，总金额约为968.9万港元。增持后最新持股数目为2130.67万股，最新持股比例为6.04%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03759","300759","BK1141","EWH","BK1576","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638695348","title":"新华健康丨康龙化成拟新建年产200吨医药中间体及API项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2638695348","media":"经济参考网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638695348?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:39","pubTimestamp":1779971975,"startTime":"0","endTime":"0","summary":"康龙化成(北京)新药技术股份有限公司（简称“康龙化成”，300759.SZ，03759.HK）5月27日晚间发布公告，公司拟通过全资子公司在绍兴上虞经开区投资30亿元(人民币，下同)，建设年产200吨医药中间体及API（ActivePharmaceuticalIngredient，简称“API”，即原料药）项目，项目分两期落地投产，将聚焦肥胖症、糖尿病、肿瘤等高端药物原料生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605283752983239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","BK1141","BK1515","03759","300759","BK1574","159938","BK0216","BK1576","BK1161"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2638668844","title":"康龙化成拟50亿元扩张产能，底气何在？","url":"https://stock-news.laohu8.com/highlight/detail?id=2638668844","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638668844?lang=zh_cn&edition=full","pubTime":"2026-05-28 15:09","pubTimestamp":1779952140,"startTime":"0","endTime":"0","summary":"国内CRO头部企业康龙化成（300759.SZ/3759.HK），同日披露两项重磅产能扩张计划，预计投资总规模将达50亿元。5月27日晚，康龙化成发布公告称，公司计划通过全资子公司康龙化成（绍兴）新药生产有限公司，斥资30亿元在绍兴市上虞区杭州湾上虞经济技术开发区内建设年产200吨医药中间体及API项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605283752721556.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605283752721556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1141","03759","BK1576","300759","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638689303","title":"公告精选︱康龙化成：拟20亿元新建新药商业化生产和CDMO研发生产服务基地；华塑控股：未从事PCB生产业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2638689303","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638689303?lang=zh_cn&edition=full","pubTime":"2026-05-27 22:33","pubTimestamp":1779892385,"startTime":"0","endTime":"0","summary":"龙芯中科：拟定增募资不超23亿元","market":"sh","thumbnail":"https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4950239","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0095","BK0145","BK1576","000509","03759","BK0216","PCB","300759","BK0236","BK4139","BK0102","BK1141","CDMO","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638507992","title":"4家CRO，减员5797人","url":"https://stock-news.laohu8.com/highlight/detail?id=2638507992","media":"赛柏蓝","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638507992?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:38","pubTimestamp":1779881880,"startTime":"0","endTime":"0","summary":"十家头部CRO企业员工总数从97918人增至98299人，增幅0.39%。表面看人数基本稳定，但内部差异化显著，药明康德、九洲药业、昭衍新药、毕得医药合计减少5797人；康龙化成、泰格医药、凯莱英仍在加人。01CRO扩员红利见顶2025年，国内头部CRO企业的人力扩张基本停了下来。两家公司一减一增，说明CRO人员扩张只会流向更明确的业务方向。此外，康龙化成在2026年一季度收入35.78亿元，同比增长15.48%；归母净利润3.35亿元，同比增长9.75%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-05-27/doc-inhzivfk8415193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03347","BK1583","06127","03759","06821","BK1191","BK1141","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638020165","title":"康龙化成：拟投资30亿元建年产200吨医药中间体项目 分期至2030年完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2638020165","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638020165?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:31","pubTimestamp":1779881460,"startTime":"0","endTime":"0","summary":"5月27日，康龙化成（300759/03759）发布公告，公司计划通过全资子公司康龙化成（绍兴）新药生产有限公司，在绍兴市上虞区投资建设年产200吨医药中间体及API项目。项目的总投资金额为30亿元，旨在扩大高端医药中间体及原料药的产能规模，强化绿色制造技术的应用能力，并提升公司的CDMO服务能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605273751465310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","09939","BK1515","BK1141","03759","159938","BK1576","300759","BK1574","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638502392","title":"康龙化成最新公告：拟投资20亿元在杭州建设新药商业化生产和CDMO研发生产服务基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2638502392","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638502392?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:21","pubTimestamp":1779880875,"startTime":"0","endTime":"0","summary":"康龙化成(300759.SZ)公告称，公司拟在杭州市钱塘区投资约20亿元新建新药商业化生产和CDMO研发生产服务基地，并于2026年5月27日与杭州市钱塘区招商服务中心签订《投资协议》。项目预计2029年投入使用，旨在提升小分子药物和新型分子药物商业化生产及CDMO研发生产服务能力，支持项目管线向后期临床和商业化阶段转化。项目尚处筹备阶段，存在不确定性风险。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700040247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300759","BK0216","03759","BK1576","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637312650","title":"康龙化成追加2.83亿元投资宁波甬康，累计认缴出资额达4.33亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637312650","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637312650?lang=zh_cn&edition=full","pubTime":"2026-05-22 20:58","pubTimestamp":1779454680,"startTime":"0","endTime":"0","summary":"5月22日，康龙化成（300759/03759）发布公告，公司以自有资金向宁波甬康追加投资2.83亿元参与本次扩募。本次追加投资完成后，公司对宁波甬康认缴出资额共计4.33亿元。本次追加投资完成后，基金合伙人及认缴出资情况如下：2026年一季度，康龙化成实现收入35.78亿元，归母净利润3.35亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605223747008786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1576","03759","BK1141","300759","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637527338","title":"Ariel Investments, LLC增持康龙化成(03759)90.07万股 每股作价约18.28港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637527338","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637527338?lang=zh_cn&edition=full","pubTime":"2026-05-21 19:05","pubTimestamp":1779361549,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月18日，Ariel Investments, LLC增持康龙化成(03759)90.07万股，每股作价18.2754港元，总金额约为1646.07万港元。增持后最新持股数目为1778.99万股，最新持股比例为5.04%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","BK1576","300759","EWH","BK1141","03759"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pharmaron.com","stockEarnings":[{"period":"1week","weight":-0.0577},{"period":"1month","weight":-0.1832},{"period":"3month","weight":-0.2146},{"period":"6month","weight":-0.3065},{"period":"1year","weight":-0.0793},{"period":"ytd","weight":-0.2078}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0294},{"period":"6month","weight":-0.0485},{"period":"1year","weight":0.0284},{"period":"ytd","weight":-0.0356}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康龙化成（北京）新药技术股份有限公司是一家主要从事医药研发的中国公司。该公司运营五个分部。实验室服务分部主要包括实验室化学和生物科学服务，服务项目涵盖小分子化学药、寡核苷酸、多肽、抗体、抗体偶联药物和细胞与基因治疗产品等。化学和制剂工艺开发及生产服务分部包括原料药工艺开发及生产以及预制剂、制剂开发。临床研究服务分部包括国外临床研究服务和国内临床研究服务。大分子和细胞与基因治疗服务分部包括大分子药物发现及开发与生产服务和细胞与基因治疗实验室及基因治疗药物开发与生产服务。该公司还通过其他分部开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":-0.020001},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.03401},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.039469},{"month":4,"riseRate":0.857143,"avgChangeRate":0.052264},{"month":5,"riseRate":0.571429,"avgChangeRate":-0.00668},{"month":6,"riseRate":0.571429,"avgChangeRate":0.048742},{"month":7,"riseRate":0.666667,"avgChangeRate":0.081227},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.032342},{"month":9,"riseRate":0.666667,"avgChangeRate":0.134004},{"month":10,"riseRate":0.5,"avgChangeRate":-0.053116},{"month":11,"riseRate":0.333333,"avgChangeRate":0.03614},{"month":12,"riseRate":0.571429,"avgChangeRate":0.025859}],"exchange":"SEHK","name":"康龙化成","nameEN":"PHARMARON"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康龙化成(03759)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康龙化成(03759)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康龙化成,03759,康龙化成股票,康龙化成股票老虎,康龙化成股票老虎国际,康龙化成行情,康龙化成股票行情,康龙化成股价,康龙化成股市,康龙化成股票价格,康龙化成股票交易,康龙化成股票购买,康龙化成股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康龙化成(03759)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康龙化成(03759)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}